GoIndustry DoveBid appoints SVP of North American sales
Romie Castelli returns to the company he originally joined in 2002
Castelli takes responsibility for directing GoIndustry DoveBid’s sales and marketing efforts in North America. He was most recently senior vice president of corporate services at Great American Group. Before that, as senior vice president of North America at DoveBid, prior to its acquisition by GoIndustry in 2008, he was responsible for the DoveBid sales force.
Castelli joined DoveBid in 2002 through acquisition, having been vice president of sales for ZoneTrader.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development